基于血清游离DNA的鸟分枝杆菌复合群感染检测
本研究开发并优化了一种基于CRISPR的鸟分枝杆菌复合群(MAC)游离DNA(cfDNA)检测方法,并在两个MAC疾病队列中评估其诊断和预后性能。结果显示,该检测总体灵敏度为97.6%(91.6-99.7%),特异度为97.6%(91.5-99.7%),且在接受MAC导向治疗并出现培养转阴的患者中,血清MAC cfDNA浓度显著下降。
要点
- CRISPR MAC检测在MAC肺病中灵敏度97.6%、特异度97.6%。
- 治疗开始后,培养转阴患者血清MAC cfDNA浓度显著下降。
- 该检测有望快速诊断MAC感染并监测治疗反应。
核心结论
- 本研究为基于血清的CRISPR MAC检测快速识别MAC感染和监测治疗反应提供了初步证据。
研究设计与样本
- 研究开发并优化了CRISPR MAC检测,并在两个MAC疾病队列中评估诊断性能。
- 诊断性能分析使用两个队列的治疗前血清,并在接受大环内酯类多药方案的MAC肺病患者亚组中评估治疗期间血清MAC cfDNA变化。
主要发现
- CRISPR MAC检测在MAC肺病中总体灵敏度为97.6%(91.6-99.7%),特异度为97.6%(91.5-99.7%)。
- 在MAC导向治疗开始后,出现MAC培养转阴的MAC肺病患者血清MAC cfDNA浓度显著下降。
临床怎么用
- 该血清CRISPR MAC检测有望用于快速检测MAC感染并监测抗菌治疗反应。
局限性
- 本研究仅提供初步证据,尚需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Mycobacterium avium complex (MAC) is the most common cause of nontuberculous mycobacterial (NTM) pulmonary disease (PD), which exhibits increasing global incidence. Current microbiologic methods routinely used in clinical practice lack sensitivity and have long latencies, leading to delays in diagnosis and treatment initiation and evaluation. A clustered regularly interspaced short palindromic repeats (CRISPR)-based assay that measures MAC cell-free DNA (cfDNA) concentrations in serum could provide a rapid means to detect MAC infection and monitor response to antimicrobial treatment. Objectives: To develop and optimize a CRISPR MAC assay for MAC infection detection and to evaluate its diagnostic and prognostic performance in two MAC disease cohorts. Methods: MAC cfDNA serum concentrations were measured in individuals with diagnoses of MAC disease or who had bronchiectasis or chronic obstructive pulmonary disease diagnoses without histories of NTM PD or NTM-positive sputum cultures. Diagnostic performance was analyzed using pretreatment serum from two cohorts. Serum MAC cfDNA changes during MAC PD treatment were evaluated in a subset of patients with MAC PD who received macrolide-based multidrug regimens. Measurements and Main Results: The CRISPR MAC assay detected MAC cfDNA in MAC PD with 97.6% (91.6-99.7%) sensitivity and 97.6% (91.5-99.7%) specificity overall. Serum MAC cfDNA concentrations markedly decreased after MAC-directed treatment initiation in patients with MAC PD who demonstrated MAC culture conversion. Conclusions: This study provides preliminary evidence for the utility of a serum-based CRISPR MAC assay to rapidly detect MAC infection and monitor the response to treatment.
引用
- Li L, Henkle E, Youngquist BM, et al. Serum Cell-Free DNA-based Detection of Mycobacterium avium Complex Infection. Am J Respir Crit Care Med. 2024. PMID: 38190702. doi:10.1164/rccm.202303-0401OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。